JAMA Network
About The Study: This analysis found that racial and ethnic disparities in buprenorphine treatment duration increased between 2006 and 2020, particularly during more recent years. Buprenorphine is used to treat opioid use disorder and reduce overdose risk. Duration of buprenorphine treatment is a measure of quality of care; longer retention is associated with superior clinical outcomes.
Authors: Mohammad S. Jalali, Ph.D., of Harvard Medical School in Boston, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(10.1001/jamapsychiatry.2022.3673)
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
